Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 15/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | XBP1 | P17861 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029308 | 0.89 | ALOX15 (0.74) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL4077176 | 0.89 | ALDH1A1 (0.69) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL4358217 | 0.88 | ALOX15 (0.81) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL8793660 | 0.87 | ALOX15 (0.85) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL14174311 | 0.86 | ALOX15 (0.70) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL26213307 | 0.86 | ALOX15 (0.70) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL4045222 | 0.85 | ALOX15 (0.69) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL1121564 | 0.84 | KDM4E (0.59) | ALOX15ALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL11559665 | 0.84 | ALDH1A1 (0.70) | ALOX15ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL469602 | 0.84 | ALOX15 (1.00) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022008475-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2022-01-13 | — | — | WO | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | MKI67, FLT4, IDO1 | ALOX15 1095/4885ALDH1A1 98/4885HPGD 416/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | ALOX15 1001/4885ALDH1A1 1203/4885HPGD 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.